An interventional study of Peripheral thrombectomy system in Deep Vein Thrombosis (DVT), sponsored by BrosMed Medical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by BrosMed Medical Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Venous Thrombosis with a site in China — 16 open to participants now, 18 under way, 2 of them phase 3. Venous Thrombosis · China.
Among the 59 studies in Venous Thrombosis with a site in China, this one is the 26th largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 58th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →16 of the 59 studies in Venous Thrombosis with a site in China are open now. Recruiting first, the newest first:
RenJi Hospital · Sites in China
Ages 18–85
Chinese PLA General Hospital · Sites in China
Ages 18–70 · Healthy volunteers
China-Japan Friendship Hospital · Sites in China
Ages 14+
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–100
Peking University People's Hospital · Sites in China
Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 17 · Phase 4 6
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 167 is close to the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 360 across the 41 interventional studies, 600 across the 17 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 59 have an industry lead sponsor. The 10 most frequent:
BrosMed Medical Co., Ltd is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
BrosMed Medical Co., Ltd has 1 study filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Venous Thrombosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04649489Phase 3Jia FanA Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | 2027-08-31 |
| NCT05588284Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityPreservation of Venous Valvular Function After PMT for Acute DVT | 2026-12-30 |
| NCT04694248First Affiliated Hospital of Zhejiang UniversityAnticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | 2026-12-31 |
| NCT05286710RenJi HospitalRheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Venous Thrombosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study plans to enroll 167 subjects. Subject enrollment and treatment details will be documented, and follow-up assessments will be conducted at screening, on the procedure day, before discharge, and at 1, 3, and 6 months after the procedure, to assess the safety and efficacy of the peripheral thrombectomy system for the treatment of lower extremity deep vein thrombosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Thrombectomy system
Device: Peripheral thrombectomy system
For the subjects who met the requirements of the study protocol, the BM peripheral thrombectomy system was used for treatment.
Technical success rate
≥50% thrombus removal in the target venous segment as assessed by venography.
Time frame: Immediately after procedure, 0 day
Major adverse events (MAE) rate
MAE is defined as all-cause death, major bleeding, symptomatic pulmonary embolism, or re-thrombosis of the target venous segment.
Time frame: 30 days
Device success rate
Device success is defined as successful delivery of the thrombectomy catheter to the target lesion, smooth deployment during the procedure, and removal.
Time frame: Immediately after procedure, 0 day
VCSS score
The number of patients that have improvement in Venous Clinical Severity Score (VCSS) which is a clinical assessment by the physician to score patient reported symptoms from a score of 0 to 3 based on severity. A score of 0 indicates absence of symptoms and a score of 3 indicates severe symptoms. The total score is the sum of all individual scores.
Time frame: Baseline, 1 Month, 6 Months
Vein Patency
The number of patients who have vein patency as measured by duplex ultrasound, CTV, or DSA.
Time frame: at 6 months
Incidence of PTS
Assessed by the Villalta score, patients with a score of ≥5 points are diagnosed with post-thrombotic syndrome (PTS).
Time frame: at 6 Months
AE and SAE
Occurrence of adverse events (AE) and serious adverse events (SAE) during the study.
Time frame: Up to 6 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.
Of 117 interventional studies with no phase under Venous Thrombosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.